SCT, secretin, 6343

N. diseases: 230; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0004352
Disease: Autistic Disorder
Autistic Disorder 		0.330 Biomarker disease BEFREE The study of the transcriptional control of human secretin and its receptor should shed light on the pathological developments of pancreatic cancer and autism in the future. 10437774 1999
CUI: C0004352
Disease: Autistic Disorder
Autistic Disorder 		0.330 Therapeutic disease CTD_human Recent observations that the deficits in social reciprocity skills seen in young (3-4-year-old) autistic children are improved after secretin infusions suggest an additional influence on neuronal activity.We show here that i.v. administration of secretin in rats induces Fos protein expression in the neurons of the central amygdala as well as the area postrema, bed nucleus of the stria terminalis, external lateral parabrachial nucleus and supraoptic nucleus. 12732234 2003
CUI: C0004352
Disease: Autistic Disorder
Autistic Disorder 		0.330 Therapeutic disease CTD_human These findings suggest that secretin promotes the metabolism of serotonin and dopamine in the central nervous system, which may contribute to improvement in clinical symptoms of autism. 15272612 2004
CUI: C0004352
Disease: Autistic Disorder
Autistic Disorder 		0.330 GeneticVariation disease BEFREE The human secretin gene: fine structure in 11p15.5 and sequence variation in patients with autism. 12160732 2002
CUI: C0004352
Disease: Autistic Disorder
Autistic Disorder 		0.330 GeneticVariation disease LHGDN While the secretin gene (SCT) was not found to be mutated in the majority of autistic patients, rare heterozygous sequence variants were identified in three patients. 12160732 2002
CUI: C0004352
Disease: Autistic Disorder
Autistic Disorder 		0.330 Therapeutic disease CTD_human After administration of secretin, the Autism Diagnostic Interview-Revised (ADI-R) score improved in 7 of the 12 children. 16168596 2006
CUI: C0004352
Disease: Autistic Disorder
Autistic Disorder 		0.330 GeneticVariation disease BEFREE We did not find evidence of a relationship between human secretin gene mutation and autism. 16225821 2005
CUI: C0004352
Disease: Autistic Disorder
Autistic Disorder 		0.330 Therapeutic disease CTD_human Since autism is hypothesized to be a hypoglutamatergic disorder we investigated the in vivo effects of secretin on extracellular amino acids in the rat brain. 15206007 2004
CUI: C0008340
Disease: Choledochal Cyst
Choledochal Cyst 		0.300 Biomarker disease CTD_human Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease. 18988797 2008
CUI: C0009439
Disease: Choledochal Cyst, Type I
Choledochal Cyst, Type I 		0.300 Biomarker disease CTD_human Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease. 18988797 2008
CUI: C0032460
Disease: Polycystic Ovary Syndrome
Polycystic Ovary Syndrome 		0.300 Biomarker disease CTD_human Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycles. 21411543 2011
CUI: C1136382
Disease: Sclerocystic Ovaries
Sclerocystic Ovaries 		0.300 Biomarker disease CTD_human Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycles. 21411543 2011
CUI: C1257796
Disease: Choledochal Cyst, Type II
Choledochal Cyst, Type II 		0.300 Biomarker disease CTD_human Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease. 18988797 2008
CUI: C1257797
Disease: Choledochal Cyst, Type III
Choledochal Cyst, Type III 		0.300 Biomarker disease CTD_human Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease. 18988797 2008
CUI: C1257798
Disease: Choledochal Cyst, Type IV
Choledochal Cyst, Type IV 		0.300 Biomarker disease CTD_human Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease. 18988797 2008
CUI: C1257799
Disease: Choledochal Cyst, Type V
Choledochal Cyst, Type V 		0.300 Biomarker disease CTD_human Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease. 18988797 2008
CUI: C0018133
Disease: Graft-vs-Host Disease
Graft-vs-Host Disease 		0.100 Biomarker disease BEFREE The risk of acute graft-versus-host disease (GVHD) is significantly higher after HID-SCT versus ISD-SCT (OR = 1.88, 95% CI = 1.42-2.49, P < 0.00001), but the relapse rate is lower in HID-SCT group (OR = 0.70, 95% CI = 0.55-0.90, P = 0.005). 29381772 2018
CUI: C0018133
Disease: Graft-vs-Host Disease
Graft-vs-Host Disease 		0.100 Biomarker disease BEFREE All patients underwent 10/10 HLA-matched peripheral blood allo-SCT (sibling donor for first and third patients and unrelated donor for the second patient; all had acute graft-versus-host disease (GVHD), and the first and third patients had chronic GVHD. 24994916 2014
CUI: C0018133
Disease: Graft-vs-Host Disease
Graft-vs-Host Disease 		0.100 Biomarker disease BEFREE A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms. 30030270 2018
CUI: C0018133
Disease: Graft-vs-Host Disease
Graft-vs-Host Disease 		0.100 Biomarker disease BEFREE Clinical options to restore immunocompetence after allogeneic-SCT are very limited as studies have raised awareness about the safety with regards to graft-versus-host disease (GVHD). 29967605 2018
CUI: C0018133
Disease: Graft-vs-Host Disease
Graft-vs-Host Disease 		0.100 Biomarker disease BEFREE The purpose of the current review is to summarize the biology of GVHD and GVL responses in preclinical models and to discuss potential novel therapeutic strategies to reduce the relapse rate after allo-SCT. 30619371 2018
CUI: C0018133
Disease: Graft-vs-Host Disease
Graft-vs-Host Disease 		0.100 Biomarker disease BEFREE We also detected host-derived pro-inflammatory antigen-presenting cells (APCs) in skin GVHD lesions after allo-SCT. 23470132 2013
CUI: C0018133
Disease: Graft-vs-Host Disease
Graft-vs-Host Disease 		0.100 Biomarker disease BEFREE We have compared prospectively the outcome and immune reconstitution of patients receiving either post-transplant cyclophosphamide (PTCY) (<i>n</i> = 30) or anti-thymocyte globulin ATG (<i>n</i> = 15) as Graft-versus-host disease (GVHD) prophylaxis after reduced-intensity conditioning (RIC) allogeneic peripheral blood stem cell (PBSC) transplantation (allo-SCT). 29545911 2018
CUI: C0018133
Disease: Graft-vs-Host Disease
Graft-vs-Host Disease 		0.100 Biomarker disease BEFREE Haplo-SCT using a post-transplant cyclophosphamide-based regimen can achieve better leukemia-free survival and graft-versus-host disease-free, relapse-free survival, lower incidence of graft-versus-host disease and non-relapse mortality as compared to anti-thymocyte globulin-based graft-versus-host disease prophylaxis in patients with acute myeloid leukemia. 27758821 2017
CUI: C0018133
Disease: Graft-vs-Host Disease
Graft-vs-Host Disease 		0.100 Biomarker disease BEFREE Donor lymphocyte infusions of HSV-tk represent a promising tool for preventing disease relapse and promoting immune reconstitution after haplo-SCT, and a unique tool for the control of GVHD. 12463592 2002